• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics Set to Join S&P MidCap 400

    5/29/24 5:48:00 PM ET
    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $JNJ alert in real time by email

    NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    June 3, 2024

    S&P MidCap 400

    Addition

    Sarepta Therapeutics

    SRPT

    Health Care

    June 3, 2024

    S&P MidCap 400

    Deletion

    Shockwave Medical

    SWAV

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sarepta-therapeutics-set-to-join-sp-midcap-400-302158643.html

    SOURCE S&P Dow Jones Indices

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $SPGI
    $SRPT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Sarepta Therapeutics Inc.
    $SRPT
    9/22/2025$50.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Sarepta Therapeutics with a new price target

    Wedbush initiated coverage of Sarepta Therapeutics with a rating of Outperform and set a new price target of $32.00

    12/9/25 8:53:25 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics upgraded by Mizuho with a new price target

    Mizuho upgraded Sarepta Therapeutics from Neutral to Outperform and set a new price target of $26.00

    11/5/25 7:25:02 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    SEC Filings

    View All

    Sarepta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    12/19/25 4:34:54 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    12/16/25 4:05:25 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form 8-K filed by Sarepta Therapeutics Inc.

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    12/11/25 7:13:42 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    8/20/24 8:00:04 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Dow Jones Indices Announces Change to the S&P/TSX Canadian Dividend Aristocrats Index

    TORONTO, Dec. 22, 2025 /CNW/ - S&P Dow Jones Indices announces the following index change to the S&P/TSX Canadian Dividend Aristocrats Index as a result of the monthly dividend review. Change will be effective prior to the open of trading on Friday, January 2, 2026. S&P/TSX Canadian Dividend Aristocrats Index – January 2, 2026 Symbol COMPANY DELETED AP.UN Allied Properties REIT For more information about S&P Dow Jones Indices, please visit www.spdji.com ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average

    12/22/25 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P 500 Q3 2025 Buybacks Post Modest 6.2% Gain to $249.0 Billion After Declining 20.1% Amidst Uncertainty in Q2; Q4 2025 Expenditures Expected to Post Similar Growth, As 2025 Anticipates a Record $1 Trillion

    S&P 500 Q3 2025 buybacks were $249.0 billion, as the expenditure increased 6.2% from Q2's $234.6 billion and down 15.1% from the record Q1 2025 $293.5 billion, and was up 9.9% from Q3 2024's $226.6 billionThe 12-month September 2025 expenditure was a record $1.020 trillion and was up 11.1% from the 12-month September 2024 expenditure of $918.4 billion Health Care and Financials significantly increased their spending, up 32.2% and 26.3% respectively over Q2 2025, as Materials and Real Estate reduced spending by 21.0% and 40.3%, respectivelyThe net buyback 1% tax reduced Q3 2025 operating earnings, which are set to post a quarterly earnings record by 0.36% and As Reported GAAP by 0.41%, as the

    12/18/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

    - TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery.- Approval builds on a trusted solution in neurovascular embolization for over 25 years. IRVINE, Calif., Dec. 18, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) – Today, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (cSDH) as an

    12/18/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Chambers Michael Andrew

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    12/19/25 4:40:45 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Estepan Ian Michael sold $294,202 worth of shares (13,187 units at $22.31), decreasing direct ownership by 6% to 193,300 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    12/18/25 8:05:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 5:02:15 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    S&P Dow Jones Indices Announces Change to the S&P/TSX Canadian Dividend Aristocrats Index

    TORONTO, Dec. 22, 2025 /CNW/ - S&P Dow Jones Indices announces the following index change to the S&P/TSX Canadian Dividend Aristocrats Index as a result of the monthly dividend review. Change will be effective prior to the open of trading on Friday, January 2, 2026. S&P/TSX Canadian Dividend Aristocrats Index – January 2, 2026 Symbol COMPANY DELETED AP.UN Allied Properties REIT For more information about S&P Dow Jones Indices, please visit www.spdji.com ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average

    12/22/25 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P 500 Q3 2025 Buybacks Post Modest 6.2% Gain to $249.0 Billion After Declining 20.1% Amidst Uncertainty in Q2; Q4 2025 Expenditures Expected to Post Similar Growth, As 2025 Anticipates a Record $1 Trillion

    S&P 500 Q3 2025 buybacks were $249.0 billion, as the expenditure increased 6.2% from Q2's $234.6 billion and down 15.1% from the record Q1 2025 $293.5 billion, and was up 9.9% from Q3 2024's $226.6 billionThe 12-month September 2025 expenditure was a record $1.020 trillion and was up 11.1% from the 12-month September 2024 expenditure of $918.4 billion Health Care and Financials significantly increased their spending, up 32.2% and 26.3% respectively over Q2 2025, as Materials and Real Estate reduced spending by 21.0% and 40.3%, respectivelyThe net buyback 1% tax reduced Q3 2025 operating earnings, which are set to post a quarterly earnings record by 0.36% and As Reported GAAP by 0.41%, as the

    12/18/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay

    12/15/25 4:27:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    S&P Global Adds Hubert Joly to its Board of Directors

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) announced today that its Board of Directors has approved the addition of Mr. Hubert Joly to the Board, effective January 2, 2026. Mr. Joly is the former Chair and Chief Executive Officer at Best Buy and is now a senior lecturer at Harvard Business School. Earlier in his career, Mr. Joly served as President and CEO of Carlson, a global hospitality and travel company. In addition to his teaching post at Harvard, Mr. Joly is a member of the Board of Directors of Johnson & Johnson and was until recently on the Board of

    12/16/25 8:05:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces Mobility Business Chief Financial Officer

    Matt Calderone, outgoing CFO of Booz Allen, named new CFO of Mobility and will lead the finance function of the standalone company NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Matt Calderone as Chief Financial Officer (CFO) of the Mobility business, joining the company by March 1, 2026. Mr. Calderone will serve as the CFO of the standalone public company through its planned separation from S&P Global and will oversee all aspects of the company's Finance function. He will report to Mr. Bill Eager, President of S&P Global Mobility, and CEO-designate of the future standalone company.

    12/16/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Corebridge Financial Set to Join S&P MidCap 400

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Corebridge Financial Inc. (NYSE:CRBG) will replace Allete Inc. (NYSE:ALE) in the S&P MidCap 400 effective prior to the open of trading on Wednesday, December 17. Canada Pension Plan Investment Board and Global Infrastructure Partners are acquiring Allete in a deal expected to close soon, pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 17, 2025 S&P MidCap 400 Addition Corebridge Financial CRBG Financials Dec 17, 2025 S&P MidCap 400 Deletion Allete ALE Utilities ABOUT S&P DOW JONES INDICES S

    12/12/25 5:51:00 PM ET
    $ALE
    $CRBG
    $SPGI
    Power Generation
    Utilities
    Life Insurance
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

    2/13/24 5:13:59 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care